908 Devices: A Record Quarter Into a 22% Drawdown
Record device shipments and NIRLab's first full quarter arrived into a market that had already sold the stock down 22%; the quiet story is AVCAD turning from subcontract to COTS vendor
MASS · Earnings Call · 2026-11-10
The print versus the tape
908 Devices reported the best operating quarter in its history on November 10 and got no credit for it in advance. Revenue of $19 million, up 35%, more than 300 devices shipped — a company record — and an installed base of roughly 4,400 units. “We delivered revenue of $19 million, up 35% year-over-year, driven by continued strength in our core business” — Kevin Knopp, Chief Executive Officer and Co-Founder · 2026-11-10, Kevin Knopp told the call. Guidance was raised at the low end to $68.5–70 million, and the adjusted EBITDA loss is tracking to the mid-single-digit millions, roughly a third of 2025's level. And yet the tape tells the opposite story. The shares are up 24% over ninety trading days, but they peaked at $12.87 on October 28 and were down 22.4% from that high by the report date. A $413 million market cap that had re-rated hard through the autumn — trailing price-to-revenue sat at 5.4x at the Q2 mark, up about 149% year over year — de-rated into a beat-and-raise. That is usually a positioning story rather than a fundamental one, and it sets up the question the call actually had to answer: is this a hardware quarter or a platform quarter? It was mostly hardware. FTIR was 55% of Q3 revenue, handheld product and service revenue rose 35% to $17.8 million, and roughly $4 million of the quarter came from a single Asia Pacific ProtectIR award. “We did mention the Asia Pacific, about $4 million came from that ProtectIR opportunity. So that was a high concentration” — Joseph Griffith, Chief Financial Officer · 2026-11-10, Joe Griffith conceded under a question about 41% of revenue landing with two customers. He was emphatic that there were no order shifts or pull-forwards from Q4 — but a quarter that good on two customers is a quarter that has to be re-earned.AVCAD: a slip that may be an upgrade
The most consequential thing on this call was buried in Q&A. AVCAD — the Army's next-generation aerosol and vapor detection program, and one of three named growth catalysts for years — has moved from subcontractor to candidate commercial vendor. Management delivered MX908 units to the office running analytical testing and evaluation, and framed it as a signal that the program is seriously considering a commercial-off-the-shelf path, with potential orders in 2027. The history matters. In March, the award was imminent:By August it had slipped: “On AVCAD, it's taking a little bit longer than we and the market expected, but our confidence in winning hasn't moved” — Kevin Knopp, Chief Executive Officer and Co-Founder · 2026-08-11, with the $10 million-plus opportunity pushed to the future and stripped from guidance. Today it carries zero revenue in the 2026 guide. What is new is the economics of the path now being contemplated:I remain very encouraged and positive that we will see an award this spring, and hence we are factoring it into some of the guidance discussion today.
That is a genuine trade: later revenue, but roughly 1,500–2,500 basis points more gross margin on the same program, because 908 would sell the finished COTS solution rather than subsystems. It also ties the company to a market-level theme rather than a company-specific hope — the Department of War procurement reform push toward speed and commercial products is showing up across defense reporters this week, from 3DA.AX to ELMT. AVCAD is no longer a single-program bet; it is a bet on a procurement doctrine.You'd expect the commercial margins to be more in that mid-50s, mid- to high 50s that we see with our other products under COTS versus more OEM level margins that might have been in the 30% to 40% range.